Tekmira Pharmaceuticals Corp., a Vancouver, British Columbia-based company developing a potentially curative regimen for chronic hepatitis B virus infection upsized its public offering to 7.5 million common shares from an earlier 6 million, priced at $20.25 per share, for gross proceeds of $151.9 million.